on Bb Biotech (isin : CH0038389992)
Edison Highlights BB Biotech's Portfolio Boost
BB Biotech, a leading biotech investor, focuses on long-term growth through investments in innovative biotech assets. The company is experiencing a significant portfolio boost as Johnson & Johnson (J&J) announced plans to acquire Intra-Cellular Therapies, a prominent holding within BB Biotech's portfolio. This acquisition comes with a 40% premium, impacting 6.1% of BB Biotech’s end-Q324 portfolio. Following J&J's announcement, BB Biotech’s net asset value (NAV) increased by 3.4%, outperforming the Nasdaq Biotech Index by 3.1 percentage points. The report by Edison discusses the broader implications of this development on the biotech sector.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Bb Biotech news